➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
Harvard Business School
Johnson and Johnson
Colorcon
McKesson

Last Updated: September 18, 2020

DrugPatentWatch Database Preview

Patent: 8,080,404

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,080,404
Title:Enzymatic decontamination
Abstract: Compositions and methods for enzymatic decontamination by inactivation of Hazardous agents are provided. Hazardous agents of microbial and chemical origin can be neutralized by H.sub.2O.sub.2. The methods described herein provide for enzymatic production of H.sub.2O.sub.2 in situ using oxidoreductase enzymes that use oxygen as an acceptor and their alcohol substrates. The enzymatically produced H.sub.2O.sub.2 and corresponding aldehydes have potent antimicrobial properties. The enzymatically produced H.sub.2O.sub.2 also can detoxify chemical agents in situ. The decontaminating power of the oxidoreductase enzymes that use oxygen as an acceptor may be amplified by addition of reagents, such as acetyl donors or base catalysts that, in the presence of H.sub.2O.sub.2, yield peroxy acid derivatives and hydroperoxy anions. Such derivatives can neutralize biological and chemical agents, thus providing a broadly applicable decontamination method. In addition, catalytic production of H.sub.2O.sub.2 in situ results in controlled synthesis of decontamination reagents at their point of use, mitigating the need to store, transport and dispose of hydrogen peroxide solutions in the field.
Inventor(s): Turetsky; Abraham L. (Baltimore, MD), Pawlowski; David R. (Bel Air, MD), Brickhouse; Mark D. (Newark, DE)
Assignee: The United States of America as represented by the Secretary of the Army (Washington, DC)
Application Number:11/328,477
Patent Claims:see list of patent claims

Details for Patent 8,080,404

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Emergent Biodefense Operations Lansing, Llc BIOTHRAX bacillus anthracis INJECTION, SUSPENSION 103821 1 1970-11-04   Start Trial The United States of America as represented by the Secretary of the Army (Washington, DC) 2025-04-05 search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Dow
McKesson
Johnson and Johnson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.